IRADIMED (IRMD) CEO Susi’s trust sells shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

IRADIMED CORP insider activity: A trust associated with CEO, President and Chairman Roger E. Susi reported three planned sales of common stock on January 20, 2026 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The Phillip Susi 2008 Dynasty Trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70. After these transactions, that trust held 2,267,500 shares of IRADIMED common stock. The filing also shows indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with the reporting person disclaiming beneficial ownership beyond his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S(1)		2,129	D	$101.03(2)	2,270,371	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/20/2026		S(1)		1,074	D	$102.03(3)	2,269,297	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/20/2026		S(1)		1,797	D	$102.7(4)	2,267,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(5)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $100.50 to $101.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $101.56 to $102.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $102.62 to $102.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRADIMED CORP (IRMD) report on this Form 4?

The filing reports that the Phillip Susi 2008 Dynasty Trust, associated with Roger E. Susi, executed three sales of IRADIMED CORP common stock on January 20, 2026.

How many IRMD shares were sold and at what prices on January 20, 2026?

The trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70, each in multiple trades within disclosed price ranges.

Were the IRMD insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

How many IRADIMED CORP shares did the Phillip Susi 2008 Dynasty Trust hold after the reported sales?

Following the reported transactions, the Phillip Susi 2008 Dynasty Trust held 2,267,500 shares of IRADIMED CORP common stock indirectly attributed to the reporting person.

What other indirect IRMD holdings are reported for Roger E. Susi?

The Form 4 shows 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, reported as indirect interests.

Does Roger E. Susi claim full beneficial ownership of all reported IRMD shares?

No. A footnote explains that the reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, and their inclusion does not admit full beneficial ownership.

What is Roger E. Susi’s role at IRADIMED CORP (IRMD) according to this filing?

Roger E. Susi is identified as a Director, a 10% Owner, and an Officer of IRADIMED CORP, with the titles CEO, President, and Chairman.